Combined pulmonary fibrosis and emphysema (CPFE) lung cancer characteristics
| Histology | |
| NSCLC/small cell carcinoma | 23/3 (88/12) |
| Adenocarcinoma | 8 (35) |
| Squamous cell | 13 (57) |
| Large cell | 1 (4) |
| Other | 1 (4) |
| Clinical staging | |
| NSCLC | |
| Stage I | 5 (21.7) |
| Stage II | 5 (17.4) |
| Stage IIIA | 3 (17.4) |
| Stage IIIB | 1 (4.3) |
| Stage IV | 9 (39) |
| Small cell lung cancer | |
| Limited disease | 3 (100) |
| Location | |
| Left/right | 12/11 (52/48) |
| Left lower lobe | 8 (31) |
| Right lower lobe | 8 (31) |
| Left upper lobe | 3 (12) |
| Right upper lobe | 3 (12) |
| Other (right middle lobe, lingula, hilar only) | 4 (15) |
| Located within 2 cm of pleural edge | 16 (64) |
| Treatment | |
| No therapy (direct hospice or palliation) | 4 (15) |
| Chemotherapy alone | 1 (4) |
| Radiation alone (including SBRT) | 7 (27) |
| Chemotherapy and radiation | 6 (23) |
| Surgical resection alone | 6 (23) |
| Surgical resection+chemotherapy or radiation | 2 (8) |
| Deaths | 21 (81) |
| Cause of death | |
| Primary cancer | 12 (55) |
| Infection | 3 (15) |
| Acute exacerbation of ILD | 1 (5) |
| Unrelated to CPFE and/or lung cancer | 2 (10) |
| Unknown | 3 (15) |
Data are presented as n (%). n=26. NSCLC: nonsmall cell lung cancer; SBRT: stereotactic body radiotherapy; ILD: interstitial lung disease.